Doctors Revision

Anxiolytics: Pharmacology, Rational Use and Dependence-Safe Prescribing

Text size
On this page

1 Overview

Anxiolytics reduce pathological anxiety. The pharmacological story is one of progressive refinement: barbiturates (dangerous, narrow index) gave way to benzodiazepines (effective and far safer in overdose, but habit-forming), which are now complemented — and for chronic anxiety largely replaced — by SSRIs and buspirone (slow but non-dependence-forming). Safe prescribing therefore means two disciplines: knowing the drugs, and knowing how to keep benzodiazepine use short, purposeful and reviewed.

GABA receptor structure (GABA-B receptor dimer)
The GABA-B receptor — a metabotropic dimer distinct from the ionotropic GABA-A receptor complex where benzodiazepines act. Both systems reduce neuronal excitability; only GABA-A is benzodiazepine-sensitive.
Chemical structure of diazepam
Diazepam — the prototypical 1,4-benzodiazepine. Structural variation within the class produces the differences in potency, half-life and clinical niche.

2 Learning Objectives

  • Explain how benzodiazepines, buspirone and other anxiolytics act, and what distinguishes dependence-forming from non-dependence-forming agents.
  • Classify benzodiazepines by duration and match agents to indications.
  • Prescribe benzodiazepines safely: indications, duration limits, tapering and review.
  • Manage benzodiazepine overdose and describe the limited, risky role of flumazenil.
  • Choose rationally for special groups — elderly, pregnancy, substance-use history.

3 GABA Pharmacology — the Target of Anxiolysis

GABA is the brain's principal inhibitory neurotransmitter. GABAA receptors are ligand-gated chloride channels; when GABA binds, chloride influx hyperpolarises the neuron. The GABAA complex carries binding sites for several drug classes: benzodiazepines (bind between α and γ subunits), barbiturates (bind elsewhere on the receptor), neurosteroids, alcohol and the Z-drugs. GABAB receptors are metabotropic (G-protein-coupled) — baclofen is their clinical ligand; benzodiazepines do not act there. Two mechanism facts explain most clinical behaviour: benzodiazepines increase the frequency of chloride-channel opening in response to GABA (they are positive allosteric modulators — they need GABA present, which is why they are safe in overdose alone), while barbiturates prolong opening and can directly gate the channel at high dose — which is why barbiturate overdose is lethal and benzodiazepine overdose usually is not.

4 Benzodiazepines

Classification by duration

Scroll the table sideways on a smaller screen.

DurationAgentsTypical use
Short-actingMidazolam, triazolamProcedural sedation; brief insomnia
IntermediateLorazepam, alprazolam, temazepam, oxazepamLorazepam: status, alcohol withdrawal; alprazolam: panic (high potency, difficult withdrawal); temazepam/oxazepam: insomnia, elderly-friendly (glucuronidation)
Long-actingDiazepam, chlordiazepoxide, clonazepamAnxiety, alcohol withdrawal (diazepam, chlordiazepoxide), epilepsy (clonazepam)

Indications

Acute situational anxiety and panic, generalised anxiety (short-term), insomnia (short-term), status epilepticus and seizure clusters, alcohol withdrawal, muscle spasm, procedural sedation, agitation (cautiously). They are not the treatment for chronic anxiety disorders, PTSD or depression — SSRIs are.

Adverse effects and hazards

  • CNS — sedation, psychomotor impairment, anterograde amnesia, paradoxical disinhibition (children, elderly), falls and hip fractures in the elderly, driving impairment.
  • Respiratory — dose-dependent depression; dangerous with alcohol, opioids and other sedatives (additive GABA effects).
  • Dependence — tolerance within days to weeks (receptor downregulation), psychological and physical dependence; withdrawal on stopping after regular use beyond a few weeks: rebound anxiety, insomnia, tremor, perceptual disturbance, and seizures and delirium in severe withdrawal — potentially life-threatening.
  • Special notes — alprazolam's short half-life and high potency make dependence and interdose withdrawal particularly severe; diazepam's active metabolites extend its effect for days in elderly patients.

Dependence and withdrawal

Withdrawal risk rises with dose, potency, duration (>4–6 weeks) and abrupt cessation. Management is a taper — typically reducing by ~10–25% of the dose every 1–2 weeks (switching to the long-acting diazepam first smooths the process), often over weeks to months with psychological support. Buspirone and pregabalin can help some patients during discontinuation; buspirone does not treat established benzodiazepine withdrawal (no GABA action).

5 Flumazenil — the Antidote with Strings Attached

Flumazenil is a competitive benzodiazepine-receptor antagonist: onset 1–2 minutes, peak 6–10 minutes, duration 20–50 minutes. It reverses sedation from conscious sedation and can diagnose/awaken in pure, known, single-agent benzodiazepine overdose. Its risks are decisive: seizures in chronic benzodiazepine-dependent patients (precipitates withdrawal — and then benzodiazepines won't work, since receptors are blocked); seizures with TCA or pro-convulsant co-ingestion; panic attacks in panic-disorder patients; re-sedation as it wears off before long-acting benzodiazepines clear. Contraindicated in mixed/unknown overdose, TCA co-ingestion, chronic dependence, seizure disorder, head injury. In practice, most benzodiazepine overdoses are managed with supportive care and airway protection, and flumazenil use is diminishing because the harms can outweigh the benefits.

6 Non-Benzodiazepine Options for Anxiety

  • SSRIs/SNRIs — first-line for chronic anxiety disorders (GAD, panic, social anxiety, PTSD): effective, non-dependence-forming, treat comorbid depression. Cost: 2–4 weeks to onset, initial jitteriness, sexual dysfunction.
  • Buspirone — a 5-HT1A partial agonist with no GABA activity: anxiolytic for GAD without sedation, amnesia, respiratory depression, or dependence/withdrawal; onset 2–4 weeks (not useful acutely); dizziness, nausea, headache; may augment SSRIs and blunt their sexual side effects; no value in benzodiazepine, alcohol or barbiturate withdrawal; avoid with MAOIs.
  • Hydroxyzine — sedating antihistamine; useful short-term, anticholinergic burden limits elderly use.
  • Propranolol — blocks peripheral adrenergic symptoms (tremor, tachycardia, sweating) for performance anxiety; not generalised treatment; caution in asthma and diabetes.
  • Pregabalin — effective for GAD (α2δ calcium-channel binding); sedation and misuse potential at higher doses; also treats neuropathic pain.
  • Z-drugs (zolpidem, zopiclone) — α1-selective GABAA agonists for insomnia, not anxiety; lower dependence than benzodiazepines but not dependence-free (complex sleep behaviours with zolpidem).
  • Psychological therapy — CBT is first-line alongside SSRIs for anxiety disorders, and is the treatment of choice for benzodiazepine discontinuation support.

7 Drug Monographs: Doses, Indications & Safety

Full monograph for each key anxiolytic, in the standard structure: mechanism → indications → adult dose → paediatric dose → adverse effects → contraindications → interactions → patient advice. Doses are standard teaching doses — confirm against the current Uganda Clinical Guidelines before prescribing.

Diazepam (long-acting benzodiazepine)

Scroll the table sideways on a smaller screen.

Diazepam — GABAA positive allosteric modulator
MechanismPotentiates GABA at GABAA receptors → increased chloride-channel opening frequency; long-acting with active metabolites (desmethyldiazepam)
IndicationsShort-term anxiety, alcohol withdrawal, muscle spasm, status epilepticus (IV/rectal), pre-procedure sedation
Adult doseAnxiety: 2–5 mg 2–3 times daily; status: 10–20 mg slow IV or rectal; alcohol withdrawal: 10–20 mg 2–4 times daily, then taper over 5–7 days; pre-procedure: 5–15 mg oral
Paediatric doseStatus febrile convulsions: 0.2–0.5 mg/kg rectal (max 10 mg); not for chronic anxiety in children
Adverse effectsSedation, drowsiness, ataxia, amnesia, dependence with regular use; accumulates in the elderly (active metabolites)
ContraindicationsSevere respiratory insufficiency, sleep apnoea, myasthenia gravis; caution in elderly, hepatic impairment, pregnancy
InteractionsAdditive with alcohol, opioids, other CNS depressants; CYP2C19/3A4 inhibitors (fluconazole, some antiretrovirals) raise levels; enzyme inducers (rifampicin, carbamazepine, phenytoin) lower its levels
Patient advice / monitoringShortest possible course; never mix with alcohol; no driving until stable; do not stop abruptly after regular use — taper; extra caution in the elderly (falls, confusion)

Lorazepam (intermediate benzodiazepine)

Scroll the table sideways on a smaller screen.

Lorazepam — GABAA positive allosteric modulator
MechanismSame GABAA mechanism; glucuronidated — no active metabolites, more predictable in liver disease and the elderly
IndicationsStatus epilepticus (first-line), panic and acute anxiety, alcohol withdrawal, agitation, pre-procedure
Adult doseStatus: 4 mg IV (0.1 mg/kg), repeat once after 10 min; anxiety: 0.5–2 mg 2–3 times daily; withdrawal: 1–2 mg 4 times daily tapering; sedation: 2–4 mg IM
Paediatric doseStatus: 0.1 mg/kg IV (max 4 mg); anxiety: 0.05 mg/kg/day divided (specialist, short-term)
Adverse effectsSedation, amnesia, paradoxical agitation (children/elderly), dependence, respiratory depression with other sedatives
ContraindicationsAs diazepam (respiratory failure, sleep apnoea, myasthenia gravis)
InteractionsAdditive CNS/respiratory depression with opioids, alcohol, antihistamines, antipsychotics; valproate and probenecid raise levels
Patient advice / monitoringPreferred benzodiazepine in liver disease and the elderly; short courses only; taper on stopping; avoid driving/sedating co-drugs

Alprazolam (high-potency intermediate benzodiazepine)

Scroll the table sideways on a smaller screen.

Alprazolam — GABAA positive allosteric modulator
MechanismHigh-affinity GABAA potentiation; high potency with short half-life and rapid onset → strong reinforcement
IndicationsPanic disorder (with/without agoraphobia); not recommended for generalised long-term anxiety
Adult dose0.25–0.5 mg 3 times daily; usual max 3–4 mg/day; lowest dose, shortest course
Paediatric doseNot recommended
Adverse effectsSedation, dependence and severe interdose withdrawal (rebound anxiety between doses), amnesia, depression
ContraindicationsAs other benzodiazepines; avoid with substance-use history
InteractionsSame additive-sedation profile; CYP3A4 inhibitors (ketoconazole, ritonavir) raise levels; CYP3A4 inducers (carbamazepine, rifampicin) lower them
Patient advice / monitoringThe most dependence-forming benzodiazepine in common use — prescribe few tablets, fixed short duration, review; never stop abruptly (seizure risk)

Clonazepam (long-acting benzodiazepine)

Scroll the table sideways on a smaller screen.

Clonazepam — GABAA positive allosteric modulator
MechanismSame GABAA mechanism; long half-life (~30–40 h) gives smooth, sustained effect
IndicationsMyoclonic and absence epilepsy, adjunct in focal epilepsy, anxiety (short-term), restless legs
Adult doseStart 0.5 mg 3 times daily or 1 mg at night; usual 1–8 mg/day in 1–3 divided doses
Paediatric doseStart 0.01–0.03 mg/kg/day (max 0.05 mg/kg/day) in 2–3 divided doses
Adverse effectsSedation, ataxia, behavioural change, dependence with long-term use; tolerance develops
ContraindicationsAs other benzodiazepines
InteractionsAdditive sedation; inducers (carbamazepine, phenytoin, rifampicin) lower its levels
Patient advice / monitoringTake consistently; do not stop abruptly (rebound seizures); review necessity regularly — tolerance limits long-term benefit

Midazolam (short-acting benzodiazepine)

Scroll the table sideways on a smaller screen.

Midazolam — GABAA positive allosteric modulator
MechanismSame GABAA mechanism; short half-life (~2–4 h), metabolised to inactive products
IndicationsProcedural/conscious sedation, pre-operative sedation, status epilepticus when no IV access (buccal/intranasal), ICU sedation
Adult doseProcedural sedation: IV titrated 0.5–2 mg boluses; IM 5 mg; buccal for status: 10 mg
Paediatric doseBuccal status: 5 mg (1–9 years), 10 mg (>10 years); premedication 0.25–0.5 mg/kg oral; procedural sedation 0.05–0.1 mg/kg IV titrated (with monitoring)
Adverse effectsSedation, respiratory depression/apnoea (dose-related — monitor), amnesia, hypotension
ContraindicationsAs other benzodiazepines; must be given with monitoring and resuscitation available
InteractionsAdditive respiratory depression with opioids (use reduced doses together); CYP3A4 inhibitors raise levels
Patient advice / monitoringHospital use with monitoring; airway equipment must be immediately available; complete amnesia is expected — reassure

Buspirone (non-benzodiazepine anxiolytic)

Scroll the table sideways on a smaller screen.

Buspirone — 5-HT1A partial agonist
MechanismPartial agonist at presynaptic 5-HT1A autoreceptors → reduced serotonergic firing and gradual 5-HT adaptation; no GABA activity
IndicationsGeneralised anxiety disorder (chronic); SSRI augmentation; not useful acutely or in withdrawal syndromes
Adult doseStart 5 mg 2–3 times daily; usual 15–30 mg/day; max 60 mg/day; effect over 2–4 weeks
Paediatric doseNot established
Adverse effectsDizziness, headache, nausea, nervousness; no sedation, amnesia, respiratory depression, dependence or withdrawal
ContraindicationsMAOIs (risk of hypertension); severe hepatic/renal impairment (caution)
InteractionsMAOIs; CYP3A4 inhibitors (itraconazole, ritonavir) raise levels; inducers (rifampicin, carbamazepine) reduce effect
Patient advice / monitoringWorks slowly — take daily, not "as needed"; safe for long-term use and for patients with substance-use history; may reduce SSRI sexual side effects

Propranolol (β-blocker for somatic anxiety)

Scroll the table sideways on a smaller screen.

Propranolol — non-selective β-adrenergic antagonist
MechanismBlocks β1/β2 receptors → blushes peripheral adrenergic symptoms (tremor, tachycardia, palpitations, sweating); crosses the blood–brain barrier
IndicationsPerformance/situational anxiety (exams, public speaking), tremor, adjunct in anxiety with somatic symptoms, hypertension, thyrotoxicosis symptoms, migraine prophylaxis
Adult dosePerformance anxiety: 10–40 mg 1 hour before the event; anxiety (off-label): 40–160 mg/day in divided doses
Paediatric dose0.2–0.5 mg/kg before events (specialist); otherwise not routine
Adverse effectsFatigue, cold extremities, vivid dreams, bradycardia, hypotension; may mask hypoglycaemia and worsen asthma
ContraindicationsAsthma/COPD with bronchospasm, severe bradycardia, 2nd/3rd-degree heart block, decompensated heart failure; caution in diabetes
InteractionsAdditive bradycardia with verapamil/diltiazem, digoxin; masks tachycardia of thyrotoxicosis and hypoglycaemia
Patient advice / monitoringPractice the dose before the big day (check tolerance); avoid abrupt withdrawal after chronic use (rebound tachycardia/hypertension); diabetics — watch for masked hypoglycaemia

Pregabalin (α2δ ligand)

Scroll the table sideways on a smaller screen.

Pregabalin — voltage-gated calcium-channel α2δ ligand
MechanismBinds the α2δ subunit of presynaptic calcium channels → reduces excitatory neurotransmitter release; no GABA activity
IndicationsGeneralised anxiety disorder, neuropathic pain, fibromyalgia, adjunct in focal epilepsy
Adult doseStart 75 mg twice daily; usual 150 mg twice daily; max 600 mg/day
Paediatric doseNot recommended under 18 for anxiety
Adverse effectsDizziness, somnolence, weight gain, oedema, blurred vision; euphoria/misuse potential at higher doses
ContraindicationsHypersensitivity; caution with substance-use history and renal impairment (dose-adjust)
InteractionsAdditive sedation with opioids, alcohol, benzodiazepines; few CYP interactions
Patient advice / monitoringBenefit builds over 1–2 weeks; dizziness on standing — rise slowly; report misuse urges; adjust dose in renal disease

8 Choosing by Indication

Scroll the table sideways on a smaller screen.

PresentationPreferred approach
GAD, panic disorder, social anxiety (chronic)SSRI/SNRI ± CBT; buspirone as alternative; benzodiazepines only short bridge at initiation if needed
Acute severe anxiety / panic attackBenzodiazepine short course (e.g. diazepam/lorazepam days, not weeks) while SSRI starts
Situational/performance anxietyPropranolol pre-event; skills training
Alcohol withdrawalChlordiazepoxide or diazepam fixed-dose or symptom-triggered regimen + thiamine
Status epilepticus / seizuresLorazepam IV first-line; clobazam/clonazepam adjuncts
InsomniaSleep hygiene first; short Z-drug or short/intermediate benzodiazepine if needed, brief duration
Anxiety with depressionSSRI covers both; avoid long-term benzodiazepine monotherapy

9 Dependence-Safe Prescribing Rules

  1. Have an exit plan before the first prescription — indication, expected duration (days to a few weeks), review date.
  2. Use the lowest effective dose, intermittent ("vocal naps") rather than around-the-clock where possible.
  3. Avoid in at-risk patients — history of substance use disorder, personality disorder, chronic insomnia as sole complaint.
  4. Never stop abruptly after regular use — taper; warn patients about rebound symptoms so they don't mistake them for relapse.
  5. Review at 2–4 weeks — continue only with clear indication; for chronic anxiety, transition to SSRI/CBT and taper the benzodiazepine.
  6. Document discussions, and prescribe small quantities.

10 Overdose & Management

  • Isolated benzodiazepine overdose — usually benign: drowsiness, slurred speech, ataxia; deep coma is unusual unless co-ingestants. Manage supportively (airway, observation); activated charcoal, dialysis and whole-bowel irrigation have no role. Complications: aspiration pneumonia, rhabdomyolysis.
  • Mixed overdose — danger multiplies with alcohol and opioids (respiratory depression); take a careful collateral history and treat the whole picture (naloxone for opioids).
  • Flumazenil — see the section above: reserved for pure, known, single-agent iatrogenic/naive overdoses with airway support ready; contraindicated in chronic users, mixed ingestions (especially TCA), epilepsy and head injury.

11 Special Populations

  • Elderly — high sensitivity: falls, cognitive impairment, paradoxical agitation; avoid long-acting agents (diazepam accumulates); if a benzodiazepine is unavoidable, use low-dose oxazepam/lorazepam (glucuronidated, no active metabolites); review sleep and anxiety for reversible causes first.
  • Pregnancy & lactation — short-acting agents (lorazepam, oxazepam) preferred if essential; third-trimester exposure can cause neonatal sedation/withdrawal; avoid near delivery where possible.
  • Substance-use disorders — avoid benzodiazepines except structured alcohol withdrawal; buspirone, SSRIs and CBT are the anxiolytic toolkit.
  • Hepatic impairment — prefer glucuronidated agents (lorazepam, oxazepam, temazepam) over oxidised ones (diazepam, midazolam).
  • Respiratory disease — caution in COPD/OSA and with opioids; benzodiazepines blunt the ventilatory response to CO₂.

12 Viva & Exam Points

  • Mechanism — benzodiazepines ↑ GABAA chloride-channel opening frequency (safe in overdose alone); barbiturates prolong opening (lethal in overdose).
  • Duration classes — short: midazolam; intermediate: lorazepam, alprazolam, oxazepam; long: diazepam, clonazepam.
  • Chronic anxiety first-line — SSRI ± CBT; benzodiazepines are a short bridge only.
  • Buspirone — 5-HT1A partial agonist; no dependence, no withdrawal, no acute effect; GAD only.
  • Withdrawal — rebound anxiety, seizures, delirium; manage with slow taper (switch to diazepam).
  • Flumazenil — competitive antagonist; seizures in chronic users and TCA co-ingestion; supportive care is the mainstay.
  • Elderly — avoid long-acting agents; falls, amnesia, paradoxical reactions.

13 References

For education only. Apply current Uganda Clinical Guidelines and local protocols when managing patients.

Leave a Comment

Your email address will not be published. Required fields are marked *

Scroll to Top